Background
Steroidogenesis decline is reported to be one of the mechanisms associated with obesity‐induced male factor subfertility/infertility.
Objectives
We explored the possible preventive/therapeutic effects of orlistat (a medication prescribed for weight loss) on obesity‐induced steroidogenesis and spermatogenesis decline.
Materials and methods
Twenty‐four adult male Sprague Dawley rats weighing 250‐300 g were randomized into four groups (n = 6/group), namely; normal control, high‐fat diet, high‐fat diet plus orlistat preventive group and high‐fat diet plus orlistat treatment group. Orlistat (10 mg/kg/b.w./d suspended in distilled water) was either concurrently administered with high‐fat diet for 12 weeks (high‐fat diet plus orlistat preventive group) or administered from week 7‐12 post‐ high‐fat diet feeding (high‐fat diet plus orlistat treatment group). Thereafter, serum, testes and epididymis were collected for analyses.
Results
Obesity increased serum leptin and decreased adiponectin levels, decreased serum and intra‐testicular levels of follicle stimulating hormone, luteinising hormone and testosterone, sperm count, motility, viability, normal morphology and epididymal antioxidants, but increased epididymal malondialdehyde level and sperm nDNA fragmentation. Testicular mRNA transcript levels of androgen receptor, luteinizing hormone receptor, steroidogenic acute regulatory protein, cytochrome P450 enzyme (CYP11A1), 3β‐hydroxysteroid dehydrogenase and 17β‐hydroxysteroid dehydrogenase were significantly decreased in the testes of the high‐fat diet group. Further, the levels of steroidogenic acute regulatory protein protein and enzymatic activities of CYP11A1, 3β‐hydroxysteroid dehydrogenase and 17β‐hydroxysteroid dehydrogenase were also significantly decreased in the testes of the high‐fat diet group. Treatment with orlistat significantly decreased leptin and increased adiponectin levels, improved sperm parameters, decreased sperm DNA fragmentation, increased the levels of steroidogenic hormones, proteins and associated genes in high‐fat diet‐induced obese male rats, with the preventive group (high‐fat diet plus orlistat preventive group) having better results relative to the treatment group (high‐fat diet plus orlistat treatment group).
Discussion and Conclusion
Orlistat attenuated impaired spermatogenesis and steroidogenesis decline by up‐regulating steroidogenic genes. This may not be unconnected to its significant effect in lowering serum leptin levels, since the hormone is known to dampen fertility potential. Therefore, orlistat may improve fertility potential in overweight/obese men.